BioNTech SE
$20.26B- Market cap
- $26.06B
- Debt
- +$2.68B
- Cash
- −$7.68B
Capital structure 91% equity / 9% debt · EV / Revenue 6.07x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $26.06B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: BNTX stock price at premium vs NI $103.76 current versus $40.40 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at NI's multiple
Implied fair value · at BNTX's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: BNTX FY 2025 (ended Dec 31, 2025) · NI FY 2025 (ended Dec 31, 2025).
Trendline
Ten fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 91% equity / 9% debt · EV / Revenue 6.07x
Capital structure 55% equity / 45% debt · EV / Revenue 5.51x · EV / EBITDA 12.95x
NI carries the larger enterprise value at $35.93B against $20.26B; NI trades on the lower EV / Revenue multiple (5.51x vs 6.07x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BioNTech SE · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
NISOURCE INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
—
1.71x
Net debt / EBITDA
Leverage against operating earnings
4.45x
5.80x
Cash and equivalents
Liquid reserves on the balance sheet
$7.68B
$110.10M
Total debt
Interest-bearing obligations outstanding
$2.68B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Moderna, Inc.
BNTX vs MRNA
GILEAD SCIENCES, INC.
BNTX vs GILD
AMGEN INC
BNTX vs AMGN
REGENERON PHARMACEUTICALS, INC.
BNTX vs REGN
INCYTE CORP
BNTX vs INCY
VERTEX PHARMACEUTICALS INC / MA
BNTX vs VRTX
CENTERPOINT ENERGY INC
BNTX vs CNP
ATMOS ENERGY CORP
BNTX vs ATO
DOMINION ENERGY, INC
BNTX vs D
SEMPRA
BNTX vs SRE
UGI CORP /PA/
BNTX vs UGI
FIRSTENERGY CORP
BNTX vs FE
$16.19B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.